Skip to main content

Table 3 PD-L1 staining patterns and neoadjuvant chemotherapy response in TNBC patients

From: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

PD-L1 staining N = 50 Class I and II (n = 22) Class III (n = 27) P value
Tumoral PD-L1 ≥ %1 25 (50 %) 11 14 0.999
TILs PD-L1 ≥ %1 23 (46 %) 14 10 0.064*
Tumoral and/or TILs PD-L1 ≥ %1 29 (58%) 14 15 0.771
Tumoral PD-L1 ≥ %5 16 8 8 0.761
TILs PD-L1 ≥ %5 21 11 10 0.398
Tumoral and/or TILs PD-L1 ≥ %5 23 12 11 0.396
Tumoral PD-L1 ≥ %10 13 7 6 0.525
TILs PD-L1 ≥ %10 15 8 7 0.538
Tumoral and/or TILs PD-L1 ≥ %10 19 10 9 0.556
Tumoral PD-L1 ≥ %20 7 4 3 0.685
TILs PD-L1 ≥ %20 6 2 4 0.678
Tumoral and/or TILs PD-L1 ≥ %20 9 4 5 0.999
  1. Tumor Infiltrating (stromal) lymphocytes (=TILs)